Management and Board of Directors


Dr. Glenn Larsen
Co-founder, President
and CEO of Aquinnah

Dr. Larsen brings a unique skill set to his role as CEO—he is both a highly experienced scientist and a skillful businessman with a Ph.D. in biochemistry and a PMD from Harvard.

He has been a drug hunter all his life and has a deep understanding of how to create successful drugs.   Dr. Larsen's track record speaks for itself:  he has led teams to advance 15 new drug candidates to clinical development and 5 drugs to commercialization with sales over $10B.

During a notable career at major pharmaceutical companies, Dr. Larsen was involved in all facets of drug research and development, including leading drug discovery teams, and advancing drug development programs through the preclinical, clinical, regulatory and commercialization stages.



Bob Carpenter

Mr. Carpenter is a pioneer in the biotechnology and healthcare industries.  He founded and was CEO of a number of successful biotech companies he took public, including Integrated Genetics and GelTex Pharmaceuticals, both of which were acquired by Genzyme.  Mr. Carpenter served on the Board of Genzyme from 1994 to 2011, most recently as Lead Director.

He also founded Boston Medical Investors in 1994 and currently serves as a Director of Good Start Genetics, Olaris Therapeutics, Immuneering Inc, Hydra Biosciences, and Lysosomal Therapeutics, Inc.

Mr. Carpenter is a graduate of West Point, Stanford University and holds an MBA from Harvard Business School.  


Dr. Ben Wolozin
Co-Founder and the Chief Scientific Officer
Professor of Pharmacology and Neurology, Boston University School of Medicine

Dr. Wolozin holds an MD and Ph.D. degree and has extensive research experience in this field. He is a distinguished scientist who identified one of the first molecular markers for the tangle pathology that accumulates in neurons in Alzheimer’s disease. He was also the first to identify the link between the use of statins (a cholesterol lowering drug) and reduced rates of Alzheimer’s disease. More recently, he discovered the role of persistent stress granules in ALS and Alzheimer’s disease.

He has won multiple awards for his research, including the prestigious Zenith Fellows Award and the A. E. Bennett award from the Society for Neuroscience. 


Daniel Geffken
Chief Financial Officer

Daniel brings more than 30 years of financial support and strategy exclusively for life sciences, with experience ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He has participated in seven initial public offerings since 2013, and has raised more than $1 billion in equity and debt securities for life science companies throughout his career. He has served as CFO and strategic

consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Along with his role at Aquinnah, Daniel is Founder and Managing Director of Danforth Advisors. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.

Travis Wager_Aquinnah.jpg

Travis T. Wager, Ph.D.
Vice President, Research

Dr. Wager is a leader in in the pharmaceutical industry. In his almost 20 years of leadership experience driving Neuroscience research and drug discovery programs at Pfizer, Dr. Wager advanced eight small molecule drug candidates to clinical development, including the first kinase inhibitor for a CNS indication. Dr. Wager became internationally recognized as an expert in the field of brain-penetrant small molecule design. His seminal

contributions tothe understanding of CNS drug physicochemical properties and the development of the CNS MPO desirability tool has enabled both small and large neuroscience pharmaceutical groups to accelerate CNS drug discovery. In addition, he has published extensively and authored almost 40 scientific papers, including two most cited papers, and is an inventor on over 30 patents, and serves on the Scientific Advisory Board of ACS Chemical Neuroscience.


Joshua D. Fox
Corporate Counsel

Josh is a leading Boston attorney specializing in life sciences, with significant expertise in general corporate law and financing strategies and transactions. He was named a "New England Super Lawyers Rising Star" in corporate law in the 2008, 2010-2016 issues of Boston Magazine. Along with his role at

Aquinnah, he is a partner andmember of the Emerging Company Practice Group at WilmerHale, where he advises on seed-stage, strategic and venture capital financings, mergers and acquisitions and initial public offerings. Josh holds a JD from Harvard Law School.